From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Latest Views & News

DSW
premium content

DSW Capital – interims, will deal volumes be “returning to normal levels” in its Q4?

Most recently on professional services licence network business DSW Capital (DSW), earlier this month with the shares up to 75p I concluded that the valuation seemed at least high enough. What about now half-year results headlined “Resilient performance with momentum building in M&A, leading to guidance upgrades”, and the shares currently at 69p?

Bearcast
premium content

Tom Winnifrith Bearcast: one month to Christmas

Starting with the festive note I look at Kingfisher (KGF), Hemogenyx (HEMO), Georgina Energy (GEX), Powerhouse Energy (PHE), ECR Minerals (ECR) and BWA (BWAF)
ECR
premium content

Doc Holliday pumping and dumping at ECR: there is a case for the defence

As you can see below, Mike Whitlow/Doc Holliday recorded an interview on behalf of ECR Minerals (ECR), which he now runs, which went out on November 21. The interviewer was Andrew Scott who is also a NED at ECR so it is not exactly a full on Paxman style grilling. So this hard sell recording went out on Thursday, this morning ECR announced a subscription, raising £950,000 gross at 0.33p.
KGF
premium content

Kingfisher – Q3 update emphasises “full year profit guidance range tightened”…but that’s not in a good way!

B&QCastoramaBrico DépôtScrewfixTradePoint and more international home improvement company Kingfisher (KGF) has issued a “Q3 Trading Update” headlined “Sales in line or ahead of the market across all our banners; full year profit guidance range tightened”. So why a currently approaching 13% lower share price response to below 260p?
LFT
premium content

Letter to FRC: please investigate Zak Mir, Lift Global Ventures and Lee Lederberg of Edwards Veeder

Hapless accountants Edwards Veeder were put on notice by myself HERE that I’d be watching the 2024 annual results from Brown Envelope Man’s Life Global Ventures (LFT). Christmas came early for me with a dog’s dinner of an effort from Lee Lederberg and I have written to my good pals at the Financial Reporting Council
Bearcast
premium content

Tom Winnifrith bonus bearcast: just a few more thoughts on Microstrategy vs Golden Prospect Precious Metals

Following on from my earlier piece on Microstrategy (Nasdaq:MSTR) and bitcoin I look at its valuation and also that of Golden Prospect Precious Metals (GPM). You may say its apples and pears but it tells you something does it not?
DIA
premium content

Dialight – interims argue “confident that further progress will be made in the second half”, but sufficient for the balance sheet position?…

Since I previously wrote on self-described “a global leader in sustainable LED lighting for industrial applications”, Dialight plc (DIA) earlier this month with the shares then falling to 120p, the shares had risen to most recently close at 130p. But what of them currently back towards 120p today on half-year results?

HEMO
premium content

Tim Kempster warns those foolish enough to own Hemogenyx

I have warned folks repeatedly about this dog. I think that short seller Tim Kempster is actually being rather too generous with his assessment of Hemogenyx (HEMO). As folks start to panic…
CEL
premium content

EXPOSE: Has Graham Bond of RSM been a very naughty boy with his Celadon homework?

Over at Celadon Pharmaceuticals (CEL) auditor Graham Bond of RSM signed off on 13 May 2024 after the Post Balance Sheet Fundraise on 10 May 2024 noted in the accounts. Given the fund raise was specifically highlighted as a relevant factor in the going concern assessment, the auditor RSM should have audited the note carefully given he must have relied on Fundraise to issue a clean going concern opinion.
Bitcoin
premium content

MicroStrategy - A possible Bitcoin short

If you think that Bitcoin is overpriced at just under $100,000 then a possible stock to short is MicroStrategy (Nasdaq:MSTR) at $422 which describes itself thus: “MicroStrategy® is the world's first and largest Bitcoin Treasury Company.” You would be following the strategy of a well-respected short seller Citron Research which initiated a short a few days ago. Its thesis was that MicroStrategy’s market capitalisation was far to far ahead of the value of its bitcoin portfolio.
Bearcast
premium content

Tom Winnifrith Bearcast: does Optibiotix need an FD and time to short bitcoin?

I discuss the staffing needs of Optibiotix (OPTI) and small caps in general and bitcoin vs gold
GPM
premium content

Golden Prospect – Late In Year 2024 Tipfest Update As Subscription Deadline Looms

Fully listed precious metals investor Golden Prospect (GPM) was my buy tip for 2024. At 39.25p per share, it is up a useful 40% thus far……and then there is that subscription issue shortly, at 35.94p. I’ve elected to take my shares, so fingers crossed I’ll get a nice bonus in a few days’ time.
Professor

Visual Aid: Top Performing Cryptocurrencies in 2024

In this graphic, we rank the top 10 cryptocurrencies by their YTD return (as of Nov. 17, 2024). The best performing cryptocurrency as of November 2024 is Dogecoin, which is considered by many to be the original “meme coin”. 

Gold

The View From The Montana Log-Cabin As Gold Attempts To Stage A Comeback

Gold closed the week at $2,716 – a country mile better than last week’s depressing $2,562, back above the $2,700 mark and back within striking distance of yet another all-time high. Gold stocks responded very positively, as can be seen on the chart of Gold against the mining ETFs GDX (majors), GDXJ (juniors) and GOEX (explorers).
Quiz
premium content

The ShareProphets Sunday Pub Quiz #268

It's time for the ShareProphets Sunday Pub Quiz. There are still no prizes! And remember, no Googling!

Professor
premium content

Sunday Long Reads: London Fish Markets, Junk Food Fights Back, Should India Only Speak Hindi?, Don Simpson, Painting Protests

Sunday is a good time to sit back, read, and forget about shares. Put the kettle on, find a comfy chair. You have the time, don't you?
Top-10

Notes from Underground – Most read articles for the week ending Nov 23

The most read non-Tom article last week is StreaksAI – interims argue AI technology developments “nearing completion” and “adequate working capital”, BUT… by Steve Moore at number 1 or number 8 including Bearcasts. 
NWOR
premium content

National World – saga continues as possible offerer Media Concierge warns it on “false and misleading statements”!

At 1:06pm yesterday ‘news media sector consolidator’ National World (NWOR) responded to a 7:00am possible offer at 21p per share ‘request for engagement from board’ announcement from its largest shareholder Media Concierge (Holdings) Limited – including stating that it is investigating “a potentially systemic pattern of historical invoicing irregularities in relation to the activities of entities affiliated with Media Concierge” and that “entities affiliated to Media Concierge are yet to provide access to the necessary documentation in accordance with National World's contractual and legal rights to enable the investigation” as well as that “entities affiliated with Media Concierge are currently inappropriately withholding revenues due to the company totaling £4.4 million”! Late in the afternoon Media Concierge responded.
Bearcast
premium content

Tom Winnifrith Bearcast: have you heard of Alastair Bath?

No me neither until Thursday. I discuss Tirupati Graphite (TGR) , V22 (V22) and Skinbiotherapeutics (SBTX)
SBTX
premium content

SkinBioTherapeutics – “finalisation of commercial agreement with Croda” to further spark the shares, Buy

SkinBioTherapeutics (SBTX) has announced, based on the final testing of its SkinBiotix technology, that it has finalised the commercial terms of an agreement with FTSE 100 speciality chemicals company Croda (CRDA). This is highly encouraging as it follows the results of additional studies which are described as “all very positive, and the product is now in the marketing and commercialisation phase” with a commercial team from Croda “which includes the launch of multimillion pound blockbuster products such as Matrixyl” (skin ingredient), whilst the current SkinBioTherapeutics market cap, at an up to 15.625p share price, is still just £35.7 million.
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 03:07:02